We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
- Authors
Bao, Philip Q; Ramanathan, Ramesh K; Krasinkas, Alyssa; Bahary, Nathan; Lembersky, Barry C; Bartlett, David L; Hughes, Steven J; Lee, Kenneth K; Moser, A James; Zeh, Herbert J, 3rd
- Abstract
There is currently no consensus about the most effective adjuvant therapy for adenocarcinoma of the pancreas. Both gemcitabine and erlotinib have been demonstrated to improve survival in patients with metastatic disease. This study was designed to evaluate the efficacy of gemcitabine and erlotinib as adjuvant therapy, and to explore potential biomarkers associated with response.
- Publication
Annals of surgical oncology, 2011, Vol 18, Issue 4, p1122
- ISSN
1534-4681
- Publication type
Journal Article
- DOI
10.1245/s10434-010-1401-9